Abstract: The invention provides compositions and methods for treating conditions in a subject by inhibiting inosine monophosphate dehydrogenase. The invention provides compositions and methods that provide periods of sustained inhibition of inosine monophosphate dehydrogenase followed by periods in which enzyme activity is not inhibited. The invention also provides methods that include monitoring inhibition of inosine monophosphate dehydrogenase via analysis of GTP levels.

Abstract: A panel assembly includes a panel member having a mounting side and at least one elongated member. The at least one elongated member includes a mounting edge, a second edge opposite the mounting edge of the at least one elongated member, and a plurality of first spaced apart openings. The panel assembly further includes at least one elongated intersecting member. The at least one elongated intersecting member includes a mounting edge, a second edge opposite the mounting edge of the at least one elongated intersecting member, and a plurality of second spaced apart openings. Further, one of the at least one elongated member and the at least one elongated intersecting member includes at least one slot, the at least one elongated member and the at least one elongated intersecting member intersecting at the at least one slot.

Abstract: A panel assembly includes a panel member, a frame member, and at least one first bar member, and at least one second bar member. The at least one first bar member and the at least one second bar member divide the panel member into a plurality of first areas defining a first height and a first width. The panel assembly also includes a plurality of support arrangements for dividing each first area into a plurality of second areas. Each support arrangement includes a first support member defining a first length such that the first width defined by the first area is greater than the first length. Each support arrangement also includes a second support member defining a second length such that the first height defined by the first area is greater than the second length.

Abstract: The invention provides therapeutic compositions that contain an inhibitor of dihydroorotate dehydrogenase (DHODH) and promote sustained elevation of dihydroorotate (DHO) levels in a patient. The compositions are useful for treating disorders associated with unregulated DHODH activity, such as acute myeloid leukemia. The invention also provides methods of determining therapeutically effective doses of compositions that contain a DHODH inhibitor. The invention further provides methods of synthesis of 2-(2?-halo-1-1?-biphenyl-4-yl)-quinoline carboxylic acids, which are useful as DHODH inhibitors.

Abstract: An energy storage device includes a plurality of energy storage cells and at least one holder structure adapted to store one or more energy storage cells of the plurality of energy storage cells. The at least one holder structure includes at least one non-rigid member overmolded to at least one rigid frame member such that the at least one non-rigid member includes one or more receiving portions dimensioned to receive at least a portion of the one or more energy storage cells therein.

Abstract: According to some embodiments, a system, method and non-transitory computer-readable medium are provided comprising receiving a node group at an integration module, wherein the node group includes one or more requests for internal data and external data, wherein internal data is data stored in an internal datastore and external data is data stored outside of the internal data store; identifying in a configuration data, one or more meta-data nodes from the node group, wherein each meta-data node indicates a request for external data; retrieving the internal data via execution of an internal data query; determining an order of execution for the one or more meta-data nodes; executing a first meta-data node based on the determined order to generate a first result; ingesting the first result into a semantic datastore; and executing a query to generate a final result, wherein the query includes the retrieved internal data and the ingested first result. Numerous other aspects are provided.

Abstract: An approach for generating an index in Darwin Information Typing Architecture (DITA) source files. The approach determines one or more similar index entries of a prioritized index. The approach determines a fraternal association exists between at least two of the one or more similar index entries when at least one of the one or more similar index entries occur with one or more similar high priority index entries. Responsive to a determination that a fraternal association exists between at least two of the one or more similar index entries, the approach determines whether an inheritance from a parent exists. The approach determines based, at least in part, on whether a fraternal association exists and whether an inheritance from a parent exists, a Darwin Information Typing Architecture (DITA) index.

Abstract: The invention provided methods of treating viral infections, such as COVID-19, by providing an agent that inhibits a nucleotide synthesis pathway. In certain methods, the agent is an inhibitor of dihydroorotate dehydrogenase, such as a brequinar. In certain methods, brequinar is provided to a subject according to a dosing regimen that tailors levels of the drug in the lungs to achieve optimal therapeutic benefit. The dosing regimen may include defined levels of brequinar administered to the subject or defined levels of brequinar attained the lungs of the subject. The invention also provides combination therapies in which an inhibitor of dihydroorotate dehydrogenase is provided together with a second therapeutic agent.

Abstract: The invention provided methods of treating viral infections, such as COVID-19, by providing an agent that inhibits a nucleotide synthesis pathway. In certain methods, the agent is an inhibitor of dihydroorotate dehydrogenase, such as a brequinar. In certain methods, brequinar is provided to a subject according to a dosing regimen that tailors levels of the drug in the lungs to achieve optimal therapeutic benefit. The dosing regimen may include defined levels of brequinar administered to the subject or defined levels of brequinar attained the lungs of the subject. The invention also provides combination therapies in which an inhibitor of dihydroorotate dehydrogenase is provided together with a second therapeutic agent.

Abstract: In some examples, an apparatus includes a battery and a dynamic voltage source coupled in series with the battery. The dynamic voltage source is to maintain (or clamp) a system voltage from going below a minimum system voltage.

Abstract: The invention provided methods of treating viral infections, such as COVID-19, by providing an agent that inhibits a nucleotide synthesis pathway. In certain methods, the agent is an inhibitor of dihydroorotate dehydrogenase, such as a brequinar. In certain methods, brequinar is provided to a subject according to a dosing regimen that tailors levels of the drug in the lungs to achieve optimal therapeutic benefit. The dosing regimen may include defined levels of brequinar administered to the subject or defined levels of brequinar attained the lungs of the subject. The invention also provides combination therapies in which an inhibitor of dihydroorotate dehydrogenase is provided together with a second therapeutic agent.

Abstract: An energy storage device includes one or more energy storage cells and at least one holder structure adapted to store at least one energy storage cell of said one or more energy storage cells. Said at least one holder structure includes a composition containing, in weight percent, of a predetermined amount of at least one thermosettable material and an effective amount of at least one curing agent and a predetermined amount of a phase change material. A method of manufacturing said at least holder structure provides high conductivity, high heat absorbing and dissipating capability, improved cooling mechanism, high thermal conductivity and characteristics resulting in minimal risk of electric short circuit between the one or more energy storage cells.

Abstract: Methods, apparatus, and processor-readable storage media for application aware cache management are provided herein. An example computer-implemented method includes maintaining a data structure comprising at least one entry indicative of an importance of at least one of a plurality of applications associated with a storage system; and controlling whether or not a particular data item requested by one of the plurality of applications is cached in a cache memory of the storage system based at least in part on the at least one entry of the data structure.

Abstract: According to some embodiments, a system, method and non-transitory computer-readable medium are provided comprising receiving a node group at an integration module, wherein the node group includes one or more requests for internal data and external data, wherein internal data is data stored in an internal datastore and external data is data stored outside of the internal data store; identifying in a configuration data, one or more meta-data nodes from the node group, wherein each meta-data node indicates a request for external data; retrieving the internal data via execution of an internal data query; determining an order of execution for the one or more meta-data nodes; executing a first meta-data node based on the determined order to generate a first result; ingesting the first result into a semantic datastore; and executing a query to generate a final result, wherein the query includes the retrieved internal data and the ingested first result. Numerous other aspects are provided.

Abstract: The invention provides therapeutic compositions that contain an inhibitor of dihydroorotate dehydrogenase (DHODH) and promote sustained elevation of dihydroorotate (DHO) levels in a patient. The compositions are useful for treating disorders associated with unregulated DHODH activity, such as acute myeloid leukemia. The invention also provides methods of determining therapeutically effective doses of compositions that contain a DHODH inhibitor. The invention further provides methods of synthesis of 2-(2?-halo-1-1?-biphenyl-4-yl)-quinoline carboxylic acids, which are useful as DHODH inhibitors.

Abstract: A plurality of triggers may be presented and a selection of a predefined trigger may be accepted. Corresponding actions for the selected trigger may then be presented and an assignment of building control components may be accepted for the corresponding actions. During subsequent operation of a building automation system, the selected trigger may be detected and the corresponding actions may then be performed on the assigned building control components.

Abstract: Live objects in heap memory exceeding a threshold size and that have not been recently accessed are compressed or offloaded to secondary memory or storage. Compressing or offloading an object can further be based on how old the object is, which can be determined based on how many garbage collections the object has survived. Objects comprising references to other objects can be split into two sub-objects, one containing value fields that is compressed or offloaded and one containing reference fields that remains uncompressed in heap memory. Heap memory can undergo compaction after objects are compressed or offloaded. Compression accelerators can be used for compression and the decision of whether to compress or offload an object can be based on accelerator throughput, latency, availability, as well as other computing system metrics or characteristics. The compressing and offloading of objects and subsequent compaction can make more heap memory available for object allocation.

Abstract: The invention provides methods for adjusting a drug dosing regimen, including a drug dosage and schedule of administration, in individuals who have previously received at least one dose of the drug. Adjustments to the dosage and/or schedule are made based on measured levels of the drug or metabolite of the drug and a biomarker of engagement of the drug with its target. The methods are useful for administration of therapeutic agents, such as brequinar, that alter metabolic pathways.

Abstract: The invention provides methods for adjusting a drug dosing regimen, including a drug dosage and schedule of administration, in individuals who have previously received at least one dose of the drug. Adjustments to the dosage and/or schedule are made based on measured levels of the drug or metabolite of the drug and a biomarker of engagement of the drug with its target. The methods are useful for administration of therapeutic agents, such as brequinar, that alter metabolic pathways.

Abstract: The invention provides therapeutic compositions that contain an inhibitor of dihydroorotate dehydrogenase (DHODH) and promote sustained elevation of dihydroorotate (DHO) levels in a patient. The compositions are useful for treating disorders associated with unregulated DHODH activity, such as acute myeloid leukemia. The invention also provides methods of determining therapeutically effective doses of compositions that contain a DHODH inhibitor. The invention further provides methods of synthesis of 2-(2?-halo-1-1?-biphenyl-4-yl)-quinoline carboxylic acids, which are useful as DHODH inhibitors.